Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bladder cancer, a two phased disease?

Mattias Höglund1

  • 1Department of Clinical Genetics, Lund University Hospital, Lund SE-221 81, Sweden. mattias.hoglund@med.lu.se

Seminars in Cancer Biology
|April 1, 2006
PubMed
Summary

Recurrent urothelial cell carcinoma (UCC) often originates from genetically altered cells within the bladder. These cells spread, forming fields of abnormal tissue that can lead to new tumor development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proliferation- and cytotoxic immune signatures identify chemotherapy-responsive bladder tumors in a molecular subtype dependent manner.

NPJ precision oncology·2026
Same author

Stage-Independent Real-Time Subtype Classification and Comprehensive Biopsy Profiling of Urothelial Carcinomas by the Lund Taxonomy System.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026
Same author

Re: Joshua J. Meeks. Urothelial Cancer: What Is the Role of Expression-based Subtypes to Guide Neoadjuvant Therapy in Muscle-invasive Bladder Cancer? Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2025.11.014.

European urology focus·2026
Same author

Evaluation of gene expression-based predictors of lymph node metastasis in bladder cancer.

Bladder cancer (Amsterdam, Netherlands)·2025
Same author

Bladder cancer subtypes exhibit limited plasticity across different microenvironments and in metastases.

Experimental hematology & oncology·2025
Same author

Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients.

JCO precision oncology·2024

Area of Science:

  • Urology
  • Oncology
  • Molecular Biology

Background:

  • Urothelial cell carcinoma (UCC) recurrence and multiplicity are significant clinical challenges.
  • Understanding the molecular mechanisms of UCC initiation, spread, and recurrence is crucial for improving patient outcomes.

Purpose of the Study:

  • To review molecular investigations on UCC initiation, spread, and recurrence.
  • To present a model for UCC development based on genetic alterations in urothelial cells.

Main Methods:

  • Review of accumulated molecular data from synchronous and metachronous UCC tumors.
  • Analysis of genetic and chromosomal changes in precursor lesions and normal urothelial cells.
  • Genetic-histological mapping of cystectomized bladders.

Main Results:

  • Most recurrent and multiple UCC tumors are monoclonal in origin.
  • Chromosomal and genetic alterations are present in precursor lesions and even normal-appearing urothelial cells.
  • Overt tumors arise in areas of genetically altered urothelium, suggesting local events.

Conclusions:

  • UCC initiation involves genetically altered, histologically normal cells.
  • Intraepithelial displacement creates fields of altered urothelium.
  • Accumulation of genetic changes in these fields leads to tumor formation and recurrence.

Related Experiment Videos